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Objectives This study assessed the comparative effectiveness of drug-eluting stents (DES) versus bare-metal stents (BMS)
among patients 85 years of age.
Background Despite an aging population, little is known about the comparative effectiveness of DES versus BMS among pa-
tients age 85 years undergoing percutaneous coronary intervention (PCI).
Methods We examined 471,006 PCI patients age 65 years at 947 hospitals in the National Cardiovascular Data Regis-
try between 2004 and 2008 and linked to Medicare claims data. Long-term outcomes (median follow-up
640.8  423.5 days) were compared between users of DES and BMS.
Results Patients age 85 years comprise an increasing proportion of PCIs performed among elderly subjects, yet rates
of DES use declined the most in this age group. Compared with BMS, use of DES was associated with lower mor-
tality: age 85 years, 29% versus 38% (adjusted hazard ratio [HR]: 0.80 [95% confidence interval (CI): 0.77 to
0.83]); age 75 to 84 years, 17% versus 25% (HR: 0.77 [95% CI: 0.75 to 0.79]); and age 65 to 74 years, 10%
versus 16% (HR: 0.73 [95% CI: 0.71 to 0.75]). However, the adjusted mortality difference narrowed with increas-
ing age (pinteraction 0.001). In contrast, the adjusted HR for myocardial infarction rehospitalization associated
with DES use was significantly lower with increasing age: age 85 years, 9% versus 12% (HR: 0.77 [95% CI:
0.71 to 0.83]); age 75 to 84 years, 7% versus 9% (HR: 0.81 [95% CI: 0.77 to 0.84]); and age 65 to 74 years,
7% versus 8% (HR: 0.84 [95% CI: 0.80 to 0.88]) (pinteraction 0.001).
Conclusions In this national study of older patients undergoing PCI, declines in DES use were most pronounced among those
aged 85 years, yet lower adverse-event rates associated with DES versus BMS use were observed. (J Am Coll
Cardiol 2012;59:105–12) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.10.853With a progressively aging U.S. population (1), there is a
need to evaluate the treatment of coronary heart disease and
associated outcomes in older adults. Previous studies con-
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PCI and DES Use Among Patients Age >85 Years January 10, 2012:105–12representation of older adults (par-
ticularly those aged 85 years) in
clinical trials, leading to lingering
uncertainty about the risk-benefit
balance of such treatments in these
patients (3).
Few studies have compared
the effectiveness and safety of
drug-eluting stents (DES) with
bare-metal stents (BMS) among
older patients for whom DES are frequently used “off-
label,” and age-related physiological changes may influence
treatment outcomes, as well as patient ability to tolerate
long-term antiplatelet therapy. Accordingly, we examined
data from the National Cardiovascular Data Registry CathPCI
(Catheterization Percutaneous Coronary Intervention) Regis-
try linked to Medicare inpatient claims to characterize the
treatment and longitudinal outcomes of older PCI patients,
particularly those age 85 years, and assess the comparative
ffectiveness of DES versus BMS among each age group.
ethods
tudy population. The CathPCI Registry is the largest
.S. registry of patients undergoing PCI. As previously
escribed (4), trained data abstractors at participating hos-
itals retrospectively collect detailed clinical information for
onsecutive PCI patients using standardized data elements
nd definitions. This study started with all PCI patients
65 years of age in the CathPCI Registry from January
004 to December 2008. International Classification of
iseases-Ninth Revision procedure codes were used to
dentify index PCI procedures in the Medicare files, which
ere then linked to CathPCI records using a combination
f indirect identifiers (5). The final study population in-
luded 471,006 patients from 947 sites successfully matched
o Medicare fee-for-service data (Fig. 1).
ata definition. Death, revascularization, and bleeding
ere defined both during the index PCI hospitalization
using CathPCI data) and post-discharge (using Medicare
ata). The International Classification of Diseases-Ninth
evision codes used to identify events were: major bleeding
430 to 432, 578.X, 719.1X, 423.0, 599.7, 626.2, 626.6,
26.8, 627.0, 627.1, 786.3, 784.7, or 459.0), revasculariza-
ion (36.00, 36.06, 36.07, 36.09, or 36.10 to 36.19), and
yocardial infarction (MI) rehospitalization (410.X1).
cute PCI was defined as PCI for ST-segment elevation
I, non–ST-segment elevation MI, or unstable angina.
tatistical analysis. Baseline characteristics and periproce-
ural treatments were categorized according to age (65 to
4, 75 to 84, and 85 years), PCI setting (acute vs.
Data Registry. All other authors have reported that they have no relationships relevant
to the contents of this paper to disclose.
Abbreviations
and Acronyms
BMS  bare metal stent(s)
DES  drug-eluting stent(s)
HR  hazard ratio
MI  myocardial infarction
PCI  percutaneous
coronary interventionp
Manuscript received August 1, 2011; revised manuscript received September 20,
2011, accepted October 11, 2011.lective), and stent type (DES versus BMS) and were
ompared using chi-square tests for categorical variables and
ilcoxon rank sum or Kruskal-Wallis tests for continuous
ariables.
The cumulative incidence rates for time-to-event out-
omes were estimated using Gray’s method. For adjusted
nalyses comparing DES with BMS, a propensity score
odel was created within each age group comparing
ES versus BMS and conditioned on 96 covariates
btained from linked clinical and claims data (6). These
ovariates included the Charlson index and recent bleed-
ng hospitalization, factors that play a significant role in
tent selection among older adults. The propensity score
ogistic regression models had c-indexes of 0.741 for ages
5 to 74 years, 0.739 for ages 75 to 84 years, and 0.747
or age 85 years. The Greedy 5¡1 Digit Matching
lgorithm was used to match each pair of device types
ased on the propensity scores. After matching, the
istribution of estimated propensity scores for DES
atients closely matched that for BMS patients. Adjusted
azard ratios (HRs) comparing DES with BMS were
alculated among matched pairs. An inverse probability–
eighted method was used as a secondary approach to
alculate adjusted HRs.
esults
aseline characteristics and treatment. Among 471,006
atients age65 years undergoing PCI in our study cohort,
2,154 (9%) were age 85 years, 187,656 (40%) were age
5 to 84 years, and 241,196 (51%) were age 65 to 74 years.
rom 2005 to 2008, the proportion of patients age 85
ears increased from 7% to 9% among those undergoing
lective PCI and from 10% to 13% among those undergoing
cute PCI (ptrend 0.001 for both). With increasing age,
lective and acute PCI patients were more likely to be
emale and white, have a higher prevalence of prior heart
ailure and stroke, and have higher Charlson index scores
Table 1).
Patients age 85 years were more likely to undergo
ultivessel PCI than younger patients (Table 2). Use of
ES decreased with age for both elective and acute PCIs.
lthough lesion complexity increased with age, the use of
ore complex PCI techniques (e.g., atherectomy) did not
iffer significantly between age groups. Periprocedural gly-
oprotein IIb/IIIa inhibitor use decreased with age. Bivali-
udin and low-molecular-weight heparin use increased with
ge among elective PCI patients.
utcomes across age groups. In-hospital mortality rates
ere significantly higher among patients age 85 years
ompared with younger patients. The mean duration of
ollow-up post-discharge was 640.8  423.5 days. Patients
85 years of age had the highest long-term mortality
mong any group, regardless of PCI setting (Fig. 2). Higher
ates of MI rehospitalization and bleeding occurred among
atients age 85 years undergoing acute PCI. Repeat
107JACC Vol. 59, No. 2, 2012 Wang et al.
January 10, 2012:105–12 PCI and DES Use Among Patients Age >85 Yearsrevascularization rates were lowest among patients age 85
years treated with acute PCI. These associations persisted
after multivariable adjustment (Fig. 3).
Figure 1 Study Population
CMS  Centers for Medicare and Medicaid Services; NCDR  National Cardiovas
Baseline Characteristics Compared Among Age Groups and StratifiTable 1 Baseline Characteristics Compared Among Age Groups
Characteristics
Elective PCI
Age 65–74 yrs
(n  174,384)
Age 75–84 yrs
(n  134,679)
Demographic
Age, yrs 69.0 (67.0–72.0) 79.0 (77.0–81.0)
Male 62.7 54.9
White race 87.4 89.8
Clinical history
Bleeding hospitalization in
previous year
0.5 0.7
Prior MI 26.9 27.0
Prior CABG 24.6 26.7
Prior PCI 33.1 31.3
Prior heart failure 12.5 16.4
Prior stroke 14.5 18.9
Peripheral vascular disease 15.3 17.6
Diabetes 38.5 32.7
Hypertension 83.3 84.5
Chronic lung disease 19.9 19.3
Dialysis 2.1 1.8
CrCL among nondialysis, ml/min 58.1 (46.4–70.6) 44.9 (35.4–55.6)
Charlson index
0 75.7 71.0
1 21.2 25.3
2 2.5 3.1
3 0.6* 0.6*
Pre-procedural cardiogenic shock 0.7 0.8Values are median (interquartile range) or %. All p values 0.05 except where denoted by asterisk.
CABG  coronary artery bypass graft; CrCL  creatinine clearance; IQR  interquartile range; MI  mComparison of DES and BMS. Between 2005 and 2008,
rates of DES use dropped across all age groups, but the
largest decline occurred among patients age85 years (Fig. 4).
ata Registry; PCI  percutaneous coronary intervention.
cording to Elective and Acute PCIStratified According to Elective and Acute PCI
Acute PCI
ge >85 yrs
 26,540)
Age 65–74 yrs
(n  66,812)
Age 75–84 yrs
(n  52,977)
Age >85 yrs
(n  15,614)
0 (85.0–88.0) 69.0 (67.0–72.0) 79.0 (77.0–81.0) 87.0 (86.0–89.0)
47.6 63.7 51.9 41.4
91.2 86.7 89.3 90.8
0.8 0.4 0.6 0.9
28.5 22.6 23.3 22.9
21.7 16.9* 19.4* 13.8*
29.0 23.7 22.4 19.1
22.0 9.4 13.6 16.9
20.6 12.0 16.8 18.7
17.0 11.9 14.4 13.3
24.1 31.7 29.2 22.2
84.8 75.0 78.6 80.0
16.7 18.6 18.6 14.8
1.3 1.9 1.8 1.2
0 (27.5–43.8) 57.8 (45.9–70.2) 43.7 (34.0–54.6) 33.6 (26.1–42.3)
59.9 26.2 25.0 18.6
35.3 68.8 68.8 75.0
4.1 3.8 5.0 5.5
0.6* 1.2 1.2 0.9
1.0 6.4 7.3 8.3cular Ded Acand
A
(n
87.
35.yocardial infarction; PCI  percutaneous coronary intervention.
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PCI and DES Use Among Patients Age >85 Years January 10, 2012:105–12During elective PCI, DES were less frequently used among
patients with prior coronary artery bypass graft or stroke
(Table 3). Regardless of PCI indication, DES were more
commonly used among patients with low Charlson index
cores and those undergoing multivessel PCI (Table 4). Risk-
djusted mortality was lower among DES patients than among
MS patients; however, this difference narrowed with increas-
ng age (pinteraction0.001) (Table 5). Risk of MI rehospital-
zation was also significantly lower among DES patients than
mong BMS patients, with greater risk difference observed
ith increasing age (pinteraction0.001). Use of DES was not
ssociated with lower revascularization risk among patients age
85 years. Bleeding risk was similar between DES and BMS
atients across all age groups.
iscussion
everal insights emerge from this study, which represents,
o the best of our knowledge, the largest report of PCI
atients age 85 years to date. First, among older patients,
n increasing proportion of PCIs are performed in those
85 years of age. Second, DES use declined significantly
ince 2005, with the largest decrease among those age 85
ears. Third, compared with BMS use, DES use was
Procedural Characteristics Compared Among Age Groups and StratTable 2 Procedural Characteristics Compared Among Age Grou
Variable
Elective PCI
Age 65–74 yrs
(n  174,384)
Age 75–84 yrs
(n  134,679)
Femoral access 97.8 97.9
Distribution of coronary disease
Single-vessel disease 45.3 41.6
2-vessel disease 30.8 31.0
3-vessel disease 22.9 26.5
ACC/AHA type C (complex) lesions 38.6 39.8
Multivessel PCI 15.7 16.5
2 Stents per patient 36.6 36.9
Procedural devices
Bare-metal stent 22.3 26.3
Drug-eluting stent 75.0 70.7
Sirolimus-eluting 41.5* 41.7*
Paclitaxel-eluting 51.6* 51.3*
Everolimus-eluting 5.7* 5.6*
Zotarolimus-eluting 2.8 2.9
Cutting balloon 4.6* 4.7*
Atherectomy 1.3 1.7
Closure device 47.5 46.6
Periprocedural pharmacology
Unfractionated heparin 48.1 48.5
Low-molecular-weight heparin 14.5 15.3
Bivalirudin 45.7 46.0
Glycoprotein IIb/IIIa inhibitors 33.2 30.4
Procedure success 94.5* 94.5*
In-hospital mortality 0.5 1.0
Values are %. All p values 0.05 except where denoted by asterisk.
ACC  American College of Cardiology; AHA  American Heart Association; other abbreviationssociated with lower mortality and MI risks across all older fge groups without significant difference in repeat revascu-
arization risk.
Although surgical revascularization offers similar or better
utcomes compared with PCI (7,8), concerns regarding
hysical and neurocognitive recovery limit its use among
any older adults (9). We observed a greater uptake of
ewer periprocedural anticoagulant agents that minimize
leeding risk among older patients than younger patients.
hus, the increasing proportion of PCI patients age 85
ears shown in this study may reflect both an aging
opulation as well as an increased willingness of providers to
onsider PCI given the contemporary low rates of peripro-
edural complications (10).
Pivotal DES trials have found a reduction in the need for
epeat revascularization but no significant differences in
ortality and MI risks compared with BMS (11,12).
evertheless, these trials enrolled very few elderly patients
2% age 85 years), and no dedicated, randomized
ES-to-BMS comparison has been performed among
hose aged65 years. In the observational setting, however,
se of DES has been associated with lower risks of mortality
nd MI (6,13,14). Our study expands on the existing
iterature by focusing on patients85 years of age, adjusting
According to Elective and Acute PCInd Stratified According to Elective and Acute PCI
Acute PCI
ge >85 yrs
n  26,540)
Age 65–74 yrs
(n  66,812)
Age 75–84 yrs
(n  52,977)
Age >85 yrs
(n  15,614)
98.2 97.9 98.1 98.6
36.4 40.4 36.0 31.4
32.7 33.0 33.4 34.8
30.2 26.0 30.0 33.4
43.2 51.8 52.7 55.5
19.1 11.0 12.6 14.5
38.6 36.5 36.7 38.5
32.8 30.4 33.7 41.2
64.0 64.5 60.7 52.8
40.6* 42.1* 41.8* 42.8*
51.2* 50.3* 50.5* 48.9*
6.2* 6.3* 6.3* 6.7*
3.7 2.9* 3.0* 3.4*
4.7* 2.6* 2.7* 2.5*
2.3 0.7 1.0 1.2
47.7 46.8 46.1 46.2
48.6 69.0 68.2 68.0
18.2 20.9* 20.7* 20.8*
47.4 25.5 27.7 29.0
26.2 59.5 53.7 47.9
94.1* 92.3 91.7 90.6
2.2 3.6 6.3 10.7
able 1.ifiedps a
A
(or a comprehensive list of variables relevant to stent
109JACC Vol. 59, No. 2, 2012 Wang et al.
January 10, 2012:105–12 PCI and DES Use Among Patients Age >85 YearsFigure 2 Unadjusted Rates of Long-Term Adverse Outcomes
Each line represents the cumulative incidence of each outcome stratified according to age and percutaneous coronary intervention (PCI) type.
(A) mortality; (B) myocardial infarction (MI) rehospitalization; (C) revascularization; and (D) bleeding.Figure 3 Adjusted Risk of Long-term Adverse Outcomes
The adjusted hazard ratios (HRs) (95% confidence intervals [CIs]) are displayed for each age group relative to patients age 65 to 74 years.
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PCI and DES Use Among Patients Age >85 Years January 10, 2012:105–12selection among older adults, and using several adjustment
methods to provide consistent results. In contrast to previ-
ous studies (6,13), DES use was not associated with lower
repeat revascularization risk among older adults, which may
in part be driven by a less invasive attitude in this patient
population. However, DES in patients age 85 years were
associated with a lower risk of MI rehospitalization com-
pared with younger patients.
With reports highlighting the risks of DES thrombosis
(15), we observed a decline in DES use, with the largest
Figure 4 Trends in DES Use Over Time
Each line represents the incidence of drug-eluting stent (DES) use over time strati
value for trend in age range 65 to 74 years, 0.0001; in age range 75 to 84 yea
cedure year trend, 0.0001. Elective PCI: p value for trend 0.0001 for all age g
Unadjusted Comparison of Baseline Characteristics Between DES aStr tified Acc rding t Age Group: Elective PCITable 3 Unadjus ed Comparison of B seline Characteristics BeStratified According to Age Group: Elective PCI
Characteristic
Age 65–74 yrs
DES
(n  130,774)
BMS
(n  32,320
Male 62.1 65.0
White race 87.5* 87.1*
Prior MI 26.2 27.6
Prior CABG 23.2 27.9
Prior PCI 33.4 27.9
Prior heart failure 11.5 15.4
Prior stroke 13.9 16.4
Peripheral vascular disease 14.4 17.8
Diabetes 38.2 38.8
Hypertension 83.0 83.5
Chronic lung disease 19.0 23.2
Dialysis 1.8 3.2
Hospitalized with bleeding in previous year 0.4 0.7
CrCl among nondialysis, ml/min 58.1 (46.5–70.5) 58.3 (46.2–71
Charlson index
0 77.4 70.2
1 20.0 25.5
2 2.2 3.4
3 0.5 1.0
Multivessel PCI 17.7 11.4
ACC/AHA type C (complex) lesions 38.7 37.2Values are % or median (interquartile range). All p values 0.05 except where denoted by asterisk.
BMS  bare-metal stent(s); DES  drug-eluting stent(s); other abbreviations as in Tables 1 and 2.drop occurring among patients age 85 years. The
possibility that DES may confer a greater clinical benefit
for this high-risk population should be considered. This
finding may reflect an outcome difference not observed in
randomized trials simply as a function of inadequate
statistical power or may represent true differences in DES
performance in a community population for whom more
than two-thirds of DES implantations were for nonap-
proved indications (14). Treatment goals for older adults
differ from those of younger patients. Reducing repeat
cording to age and percutaneous coronary intervention (PCI) type. Acute PCI: p
01; in age group 85 years, 0.0001; interaction between age group and pro-
interaction between age group and procedure year trend: 0.0001.
MS Usersn DES and BMS Users
Age 75–84 yrs Age >85 yrs
DES
(n  95,256)
BMS
(n  30,195)
DES
(n  16,993)
BMS
(n  7,595)
54.1 57.0 47.3* 48.0*
89.8 90.2 91.3* 91.1*
26.5 27.4 27.9* 28.8*
25.4 29.0 20.7 22.8
32.0 26.2 30.0 24.8
15.5 18.7 21.0 23.6
18.3 20.5 19.8 21.6
16.8 19.6 16.3 17.6
32.4* 32.7* 23.9* 24.5*
84.4* 84.5* 84.4 85.5
18.5 21.7 16.3 17.6
1.6 2.2 1.2 1.5
0.6 1.0 0.7 1.0
45.0 (35.5–55.5) 44.7 (35.2–55.7) 35.0 (27.6–43.8)* 35.2 (27.4–43.9)*
72.8 66.0 61.9 55.8
23.9 29.0 34.0 38.2
2.7 4.1 3.6 5.1
0.5 0.9 0.5 0.9
18.8 12.8 22.0 15.9
39.9 38.1 43.5 41.9fied ac
rs, 0.0
roups;nd Btwee
)
.3)
k.
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January 10, 2012:105–12 PCI and DES Use Among Patients Age >85 Yearsrevascularization risk may be less of a priority whereas the
desire to maximize quality of life by avoiding MI rehos-
pitalization may take precedence for patients age 85
years. As such, our study supports consideration of DES
use among eligible older adults. The recognition that
older adults comprise a growing proportion of PCI
patients encourages interest in trials pre-specifying an
adequately powered population of enrolled elderly pa-
tients to help correct knowledge deficits in this popula-
Unadjusted Comparison of Baseline Characteristics Between DES aStr tified Acc rding t Age Group: Acute PCITable 4 Unadjus ed Comparison of B seline Characteristics BeStratified According to Age Group: Acute PCI
Characteristics
Age 65–74 yrs
DES
(n  43,081)
BMS
(n  18,092
Male 62.5 65.7
White race 87.1 86.2
Prior MI 22.1* 21.5*
Prior CABG 16.4* 17.0*
Prior PCI 24.2 19.6
Prior heart failure 8.8 9.8
Prior stroke 11.6 12.2
Peripheral vascular disease 11.4 12.4
Diabetes 31.6 30.8
Hypertension 75.2 73.8
Chronic lung disease 17.7 20.2
Dialysis 1.6 2.2
Hospitalized with bleeding in previous year 0.3 0.6
CrCl among nondialysis, ml/min 57.9 (46.4–70.2) 57.6 (45.6–70
Charlson index
0 29.9 18.2
1 65.9 75.5
2 3.3 4.4
3 0.9 1.9
Multivessel PCI 13.4 7.5
ACC/AHA type C (complex) lesions 50.5 53.6
Values are % or median (interquartile range). All p values 0.05 except where denoted by asteris
All abbreviations as in Tables 1, 2, and 3.
Unadjusted 900-Day Event Rates and Adjusted HRs Comparing DESTable 5 Unadjusted 900-Day Event Rates and Adjusted HRs Co
Unadjusted Rate
Outcome Age Group, yrs DES, % BMS, % p Val
Death 65–74 9.7 16.2 0.00
75–84 16.8 24.8 0.00
85 28.4 38.3 0.00
MI rehospitalization 65–74 6.7 8.2 0.00
75–84 7.4 9.2 0.00
85 9.2 11.6 0.00
Revascularization 65–74 24.2 26.0 0.00
75–84 20.2 20.4 0.66
85 14.2 13.3 0.35
Bleeding 65–74 5.0 6.2 0.02
75–84 7.6 9.2 0.11
85 9.4 9.9 0.40Interaction terms between stent type and age group for all endpoints are significant with pinteraction0.0
CI  confidence interval; HR  hazard ratio; all other abbreviations as in Tables 1 and 3.tion and incorporating outcomes of relevance (e.g., qual-
ity of life).
Study limitations. Given the observational design, associ-
ations between treatments and outcomes cannot prove
causality. Despite rigorous multivariable adjustment, resid-
ual unmeasured factors that influence stent selection and
outcomes may skew the benefit toward DES use and cannot
be fully accounted for with any adjustment methods. The
use of claims data for event classification may result in
MS Usersn DES and BMS Users
Age 75–84 yrs Age >85 yrs
DES
(n  32,178)
BMS
(n  16,004)
DES
(n  8,238)
BMS
(n  5,898)
50.8 53.4 41.6* 41.5*
89.5* 89.2* 91.1* 90.5*
23.4 21.9 23.4 21.6
19.3* 18.8* 14.0* 13.3*
23.6 18.3 21.0 15.3
13.0 14.2 16.6* 16.5*
16.0 17.5 18.2* 18.8*
14.0 15.0 13.1* 13.2*
29.3 28.3 22.3* 22.0*
78.9 77.9 80.9 78.5
17.8 20.1 15.0* 14.3*
1.6 2.1 1.1* 1.4*
0.4 0.9 0.6 1.2
44.0 (34.4–54.8) 43.3 (33.6–54.4) 34.2 (26.6–42.7) 33.0 (25.8–42.0)
28.2 19.5 21.0 15.9
66.4 73.3 73.1 77.4
4.4 5.7 5.2* 5.5*
1.0 1.6 0.7 1.2
15.4 9.6 18.2 11.5
51.7 53.4 54.6* 55.3*
sus BMS Stratified According to Age Groupring DES Versus BMS Stratified According to Age Group
Propensity Matched Inverse Probability Weighted
HR 95% CI p Value HR 95% CI p Value
0.75 0.72–0.78 0.001 0.73 0.71–0.75 0.001
0.80 0.77–0.83 0.001 0.77 0.75–0.79 0.001
0.80 0.76–0.84 0.001 0.80 0.77–0.83 0.001
0.83 0.78–0.88 0.001 0.84 0.80–0.88 0.001
0.80 0.75–0.85 0.001 0.81 0.77–0.84 0.001
0.77 0.69–0.86 0.001 0.77 0.71–0.83 0.001
0.89 0.86–0.92 0.001 0.87 0.85–0.88 0.001
0.98 0.94–1.02 0.23 0.93 0.90–0.91 0.001
0.96 0.88–1.05 0.38 0.98 0.91–1.04 0.47
0.92 0.84–1.01 0.09 0.88 0.84–0.92 0.001
0.93 0.86–1.01 0.07 0.88 0.85–0.92 0.001
0.99 0.85–1.14 0.85 0.90 0.84–0.97 0.006nd Btwee
)
.3)Vermpa
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1
1
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errors should be equally distributed between groups. Angio-
graphic data were reported without central core laboratory
adjudication. Finally, we do not have information on lon-
gitudinal medication use; this information is key to prevent-
ing long-term adverse outcomes.
Conclusions
Patients age 85 years are a growing subset of patients
ndergoing PCI in the United States. In contrast to pivotal
tent studies, there was no difference in repeat revascular-
zation between DES and BMS patients age 85 years in
our study. Compared with BMS use, DES use was associ-
ated with lower risks of MI rehospitalization among older
PCI patients, particularly among those85 years of age, yet
DES use declined the most in this age group. These results
emphasize the need to further compare the effectiveness and
safety of PCI treatments among elderly patients, focusing
on endpoints relevant to this population.
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